Cronos Group Inc. (CRON) Earnings Call Transcript & Summary
August 9, 2022
Earnings Call Speaker Segments
Operator
operatorGood morning, everyone. I'm Stacy, and I'll be serving as your conference operator for today. I'd like to welcome all of you to the Cronos Group 2022 Second Quarter Earnings Conference Call. Please note that this call is being recorded. Right now, I'll hand things over to Shayne Laidlaw from Investor Relations. Shayne, the floor is yours.
Shayne Laidlaw
executiveThanks, Stacy — and I appreciate everyone being here today as we go through Cronos' financial and business results for the second quarter of 2022. With me this morning are Mike Gorenstein, our Chairman, President and CEO, and Bob Madore, our CFO. Earlier today, Cronos put out a news release with our financial results, and that release has been filed on our EDGAR and SEDAR profile. You'll also find this information, along with the prepared remarks, posted on our website in the Investor Relations section. Before handing things over to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Those forward-looking statements rest on management's current expectations and assumptions, and they carry risks and uncertainties that might make actual results come in materially different from what those forward-looking statements project. The factors that could make actual results come in materially different from expectations are laid out in detail in our earnings materials and in our SEC filings, which you can access on our website, and those filings qualify in their entirety any forward-looking statements we make during this call. Details on non-GAAP financial measures, including reconciliations to U.S. GAAP, are likewise available in the earnings materials posted on our website. We'll now deliver our prepared remarks, after which we'll open things up for a question-and-answer session.
Shayne Laidlaw
executiveHaving said that, I'll now hand things over to Mike Gorenstein, who serves as Chairman, President and CEO of Cronos.
Mike Gorenstein
executiveThanks, Shayne, and good morning, everyone. I'd like to begin by going over how far we've come on our strategic realignment initiatives since the previous call. We've kept working hard to position Cronos for the future and to get our company ready in the near term as we navigate a macroeconomic environment that's more volatile and regulatory change with uncertain timing across our current markets and those where we might seek to operate down the road. With a substantial portion of our Canadian manufacturing shifting to GrowCo, the wind down of the Peace Naturals Campus is proceeding as planned, and we remain on track to completely stop operations at that facility by the end of the year. This changeover has gone efficiently, and we're thankful to our employees and partners for making sure our operations transitioned smoothly. The build-out of our own space at GrowCo is coming along well, and downstream processing equipment will be operational in the coming weeks. We remain pleased with cultivation operations at GrowCo and look forward to this joint venture becoming a primary supplier of our products in Canada. The cost savings we expect to achieve in GrowCo are meant to help the margin profile of our products over time, which is a critical strategic goal for us.
Mike Gorenstein
executiveFor this quarter, GrowCo reported preliminary unaudited revenue of roughly $5.2 million to customers other than Cronos. And during the year-to-date period, GrowCo has turned profitable. Just as a reminder, we serve as a lender to GrowCo and its principles. GrowCo started repaying its existing $79 million senior secured loan during the first quarter. Those loan receivables, together with our balance sheet of about $945 million in cash and short-term investments, position us well to invest in new markets as they open up. Managing the balance sheet through economic uncertainty is paramount, and our wish to keep a significant, industry-leading cash balance ahead of potential global strategic growth opportunities guided many of our decisions year-to-date. During the second quarter, we made further changes in the U.S. business as we keep evaluating the best way to position our existing infrastructure to win in the U.S. and other markets globally with the borderless products we are creating today. Over the coming months, to limit operating expenses while maintaining a foothold in the U.S., you'll see us pivot the Lord Jones brand away from the wholesale beauty category and lean into adult-use product formats. That will let us preserve the Lord Jones brand equity that should enable us to launch THC products and other cannabinoid products beyond CBD in the future.
Mike Gorenstein
executiveBeyond that, we made the choice to concentrate our efforts on the direct-to-consumer channel rather than wholesale possibilities. As we shift toward a DTC emphasis, our aim is a higher gross margin profile, and we can trim our SG&A even more. Our focus is on building borderless products and brands that can be readily tailored to emerging cannabis markets once those markets turn into commercially viable opportunities. This pivot within our U.S. business pushes us further toward our single-minded goal of creating adult-use cannabinoid products. Around the world, we remain on track to deliver $20 million to $25 million in identified savings across operating expense categories in 2022, mainly driven by savings in sales and marketing, G&A and R&D. Even as we rightsize our cost structure to strengthen the overall business, we keep making significant progress expanding our borderless product portfolio in Canada under the Spinach brand and its sub-brands SOURZ and FEELZ. During the second quarter of 2022, based on Hifyre data, Spinach held an approximate 18.6% market share in the gummies category. What's more, 3 out of 4 SOURZ ranked in the top 10 for market share in Canada in Q2, and all 5 of our gummy products across SOURZ and FEELZ that were available in the market in Q2 landed in the top 15.
Mike Gorenstein
executiveJust last week, as a way to keep extending our leadership position in the category, we introduced a gummy that contains CBN, sold under the Spinach FEELZ brand — Deep Dreamz Blueberry Pomegranate, with 10 milligrams of THC and 5 milligrams of CBN in each pack. Our plan is to carry over the wins and lessons from the gummy segment into the base category too. After we moved to offering one brand formats earlier this year, both our Spinach-based lineups and our FEELZ cultured CBG way product lines have been performing strongly in market. During July, we brought out one more rare cannabinoid item containing CBN — the Spinach FEELZ Blackberry Kush, a THC-CBN 1-gram vape — which delivers a mello and dreamy high. Back in June, working alongside Ginkgo, we hit the productivity goal for THCV, the cannabinoid that is thought to lessen the appetite-enhancing trait of THC. Spinach FEELZ serves as our platform built to provide distinctive and enhanced experiences, enabled by proprietary blends of rare cannabinoids. We're excited about the potential that THCV is anticipated to bring us, and we look forward to launching THCV products into the market down the road, adding to our expanding lineup of rare cannabinoid offerings. As a reminder, during the prior quarter we announced a strengthening of our flower portfolio in response to rising demand for the 28-gram format.
Mike Gorenstein
executiveWith the introduction of strain-specific 28-gram products, Wedding Cake and Tangerine Twist, we now hold 3 flower SKUs among the top 10 by market share as of June 2022, per Hifyre. Let me spend a moment on Cronos retail sales performance in Canada. Every figure I cite from here will be retail sales for Q2 2022, as supplied by Hifyre. Cronos posted 69% year-over-year growth in retail dollar sales, whereas the overall Canadian market rose only 23%. These differentiated gains for Cronos came from 36% growth in flower against no market growth at all, and 271% growth in vape against market growth of 34%. During most of the second quarter of 2021, we had no edibles on offer. Today we hold 14.3% market share in the broader edibles category and 18.6% market share in gummies, keeping our strong #2 position in gummies. We fell behind market growth in pre-rolls, with 9% growth versus market growth of 62%, and we have a plan to improve that trajectory through SKU architecture and innovation. Despite the challenges in the Canadian market, we remain focused on building profitable market share, drawing on our expanding portfolio of borderless products. Turning to our results in Israel.
Mike Gorenstein
executiveWe’re coming off a record first quarter for the team. During this quarter, we marked the second anniversary of launching our Peace Naturals brand. For the second quarter, branded product sales brought in $7.2 million in revenue, which was up 212% year-over-year. And as of June 30, we have sold more branded products than we did across all of 2021 — incredible growth in just 1 year. Like the macro environment and other markets in early growth phases, Israel is not without its challenges. As we know well, regulations, especially in cannabis, can change rapidly. The Israeli market is currently facing 2 regulatory challenges: a pause in cannabis imports and a slowdown in patient permit authorization by the ACAR. While we believe the pause in imports will be resolved over the coming months, we feel well equipped to manage a prolonged pod, given our domestic cultivation and third-party supplier relationships in Israel. We believe the slowdown in patient permit authorization led to an increase in competitive discount. Recently released patient permit data for July showed evidence of a recovery in patient growth, growing slightly over 2% sequentially from June. We expect these regulatory issues will be resolved over the coming months, and our business will return to strong growth.
Mike Gorenstein
executiveOur commitment in Israel is a long-term investment, and we intend to build on the leadership position we hold. Our products are still carried in virtually every pharmacy that sells medical cannabis, and during the quarter we kept our place among the top 3 by market share. As the market develops, our ongoing emphasis on quality and innovation will set us apart and foster steadier loyalty among patients and consumers to our brand, Peace Naturals. Now to Australia, where we hold roughly a 10% interest in Cronos Australia; the team there is performing at a high level during these early days of market development. Cronos Australia reported preliminary '22 revenue in the range of AUD66 million to AUD68 million, with EBITDA between AUD10 million and AUD11 million. Growth in Australia's cannabis market has accelerated and is projected to reach a market size of $400 million by the end of year 2022, compared with $230 million in calendar year 2021. We are happy with how the team is progressing in this expanding market. On to appointments in the organization. I am glad to announce that Arye Weigensberg has been appointed SVP, Head of Research and Development, having filled the role on an interim basis since November of 2021.
Mike Gorenstein
executiveArye joined Cronos back in 2019 and has been instrumental in building our innovation program from the ground up. Before stepping into the interim Head of R&D role, he served as General Manager and Vice President of Research and Technology at Cronos Research Labs. Earlier still, Arye held the CEO position at Altria Israel and the Altria Research and Development Hub. I have every confidence that Arye will push Cronos' research and innovation efforts ahead as we look toward what's next and keep expanding our borderless product portfolio. On another note, it's been some time since we've been able to talk about momentum in Washington, D.C. when it comes to cannabis reform. While we're staying conservative in how we think about it, we're glad to see things moving in the right direction. We keep witnessing a wave of legalization in various forms, state by state throughout the U.S., which is further building support for legalization at the federal level. We remain directly involved in a number of industry associations and, through our employee pack, work to push the initiative forward. Beyond engaging directly via our government affairs initiatives, we also hold an option agreement with PharmaCann, one of the largest cannabis companies in the country. We're happy with the progress they've made since merging with LiveWell Health and have confidence in their strategy going forward as a combined company.
Mike Gorenstein
executiveBeyond North America, interest in legalizing cannabis keeps expanding too, which opens up additional potential market opportunities. While the majority of these efforts remain at an early stage, we are building a portfolio of borderless products alongside strategic infrastructure and partnerships around the world, paired with an industry-leading balance sheet so we can execute when the time arrives. With that said, I'll hand things over to Bob, who will walk you through our financials.
Robert Madore
executiveThanks, Mike, and good morning to everyone. For the second quarter of 2022, the company reported consolidated net revenues of $23.1 million, which is a 48% increase compared with the second quarter of 2021. The year-over-year revenue growth came mainly from higher net revenue in the Rest of the World segment, which was driven by growth in the Israeli medical market and in the Canadian adult-use market. Consolidated gross profit for the second quarter of 2022 was $4.1 million, an improvement of $19.9 million from the second quarter of 2021. Gross margin was positive 18%, compared with negative 101% last year. The improvement versus the prior year came mainly from the absence of inventory write-downs in the current period and from increased gross profit in the ROW segment, which I'll discuss a little more shortly. Consolidated adjusted EBITDA for the second quarter of 2022 was negative $18.8 million, an improvement of $31 million from the second quarter of 2021. The improvement versus the prior year was driven mainly by better gross profit and by lower sales and marketing expenses, R&D expenses, and general and administrative expenses resulting from the company's strategic realignment initiative. Turning to our reporting segments: in the Rest of the World segment, we reported net revenue of $21.6 million in the second quarter of 2022, a 61% increase from the second quarter of 2021.
Robert Madore
executiveWhen we look at the year-over-year revenue increase, the main forces behind it were higher sales in Israel's medical cannabis market—that was up 212% versus a year earlier, largely on the strength of the flower category—along with greater sales in Canada's adult-use market, which climbed 35% year-over-year. In Canada, the cannabis extracts segment drove that expansion, and we're seeing the lift come through both from launching our gummies platform and from rolling out 1-gram vapes. For the Rest of the World segment in Q2 2022, gross profit came to $4.3 million, which is a $20.8 million gain compared with the second quarter of 2021. Gross margin landed at positive 20%, an improvement from negative 123% in the prior year. What drove that year-over-year step-up was mainly the lack of inventory write-downs that we mentioned earlier, higher cannabis flower revenue, the addition of more cannabis extract categories that generate better gross profit and gross margin than our other product categories, and finally, reduced costs for cannabis biomass. Partly offsetting those gains was weaker fixed cost absorption stemming from how the wind-down tied to exiting the Peace Naturals Campus was timed. Normally we wouldn't speak to sequential movements, but with the realignment initiatives we're working through, I believe this quarter justifies unpacking it a bit further.
Robert Madore
executiveThe margin swing between Q1 '22 and Q2 '22 came mostly from when we chose to stop cultivation at Peace Naturals Campus, which resulted in less fixed cost absorption. At the same time, we saw really strong favorability in product margin mix — we've talked a lot about growth in extract sales and year-over-year reductions in biomass purchasing costs. The strategic realignment is meant to deliver a more consistent and higher gross margin for the business going forward, and we still expect that to hold as we move through the rest of this year and beyond. For the Rest of the World segment, adjusted EBITDA in the second quarter of 2022 came in at negative $9 million, which is a $23.6 million improvement over the second quarter of 2021. That year-over-year gain was mainly the result of better gross profit and lower general and administrative expenses. Now let's turn to the U.S. segment. Net revenue for the second quarter of 2022 was $1.5 million, down 34% from the second quarter of 2021. The year-over-year decline was primarily due to lower volume stemming from reduced promotional spend and SKU rationalization efforts as the company carries out its realignment of the U.S.
Robert Madore
executiveAs Mike explained earlier, turning to that part of the business. For the U.S. segment in the second quarter of 2022, gross profit came in at negative $202,000, which is an $846,000 decrease compared with the second quarter of 2021. Gross margin stood at negative 14%, compared with a positive 29% last year. The year-over-year drop was mainly attributable to lower sales volumes and higher inventory reserves, both driven by the realignment activities. Adjusted EBITDA for the U.S. segment in the second quarter of 2022 was negative $3.9 million, an improvement of $6.8 million over the second quarter of 2021. That improvement versus the prior year was primarily the result of lower sales and marketing expenses. Now moving to our balance sheet. We finished the quarter with roughly $945 million in cash and short-term investments. Capital expenditures during the quarter totaled $1.9 million, down about 10% year-over-year, mainly because of reduced spending on property, plant and equipment in the ROW segment. We stay committed to deploying capital in a disciplined manner and only in ways that align with our strategic priorities. With that, I'll hand it back to Mike.
Mike Gorenstein
executiveThanks, Bob. By centralizing functions under shared leadership, our strategic realignment places our brands and products front and center—and that’s already delivered cost savings and faster decisions. As we operate in this constantly shifting environment, we recognize that our cash has to be spent carefully and safeguarded. We know the upcoming quarters for us could bring highs and lows, but I want to thank our committed employees, who have put in tremendous effort and keep bringing their passion for the industry and for Cronos to work with them each day. All of us are pulling in the same direction, sharply focused on product innovation, revenue growth, gross profit improvement, and thoughtfully cutting operating expenses. With that, I’ll open the line for questions.
Operator
operator<<operator_script>> Our first question comes from John Zamparo at CIBC Capital Markets.
John Zamparo
analystLet me begin with THCV — you've been watching this one closely for a while now, so it's good to see the strides you've made. Could you walk us through where things stand on the road to bringing that product to market? And what lessons from your work with the other cultured cannabinoids to date can you apply here?
Mike Gorenstein
executiveAbsolutely. There are 2 points to consider here. First, we need to make sure the product side is fully right, and second, it's about which provinces we can sell in and when. New products will be launching over the coming months, as you'll see. I'd rather not provide specific dates, since we try to steer clear of that for any new product launches. Still, much like what happened with CBG, you can expect a comparable rollout in terms of the kinds of products they go into. That said, THCV is one we're very enthusiastic about. I really believe that with each additional rare cannabinoid we offer, the opportunities expand, because they work synergistically together. It won't stop at 2 cannabinoids — we'll be able to begin combining several. So from that angle, I'd say there's greater opportunity, and it's a genuinely powerful cannabinoid that the whole team is quite excited about.
John Zamparo
analystMy next question concerns M&A. I understand the point that caution is warranted and that you're focused on preserving cash, but sector valuations keep compressing, particularly in the U.S., so I'd like to hear your current thinking on acquisition opportunities. Has your view shifted in any way, and what are you looking for given how the dynamics of the space are changing, especially with valuations as of late?
Mike Gorenstein
executiveYes. As for what we seek, View remains unchanged. Our view is still that over the long term, this industry will center on branded products. In fact, one thing you are witnessing is that valuations are shifting not only because of the macro environment but also due to price compression and, frequently, an absence of differentiation. So we do perceive that opportunities may exist. That said, we would focus more on the manner in which a company can stand apart through its brand, and on how durable we judge their performance to be as markets grow more mature and more competitive, rather than merely on infrastructure and revenue.
Operator
operatorMichael Freeman of Raymond James has our next question.
Michael Freeman
analystWell done on the quarter, and well done on the strides you’ve made with the realignment plan. My first question concerns Israel. We saw yet another quarter of impressive revenue. I’m wondering whether you might offer a bit more detail on how you anticipate this halt on imports will affect your — the coming quarters; we understand you have domestic operations and certain other means of supporting performance there, but I wonder how — if you could just provide more detail on this.
Mike Gorenstein
executiveFor the upcoming few quarters, we believe we're in good shape and see no inventory problems. And if it turned out that something extended an import pause past our expectations, we have alternative options ready that we could put in place to increase our capacity relationships in Israel. One other thing that we think could actually be beneficial is that, given what I'd call a surplus of product resulting from somewhat excessive import volumes, it may well lessen the degree of competitive discounting. And combining that with the patient growth we expect to resume, I think you'll begin to see some clearing, though we're very focused on making sure we also have sufficient redundancy in our stocking.
Michael Freeman
analystAs a follow-up, building on John's question about THCV: we were really pleased to see that milestone come through Ginkgo this quarter. And since our coverage of Ginkgo centers on this biosis process, we noticed that a comparable biosynthetic route takes you from the CBG family modules over to the THC family. We're optimistic that you might have Ginkgo, and that you might have the ability to make THCV, given the capability shown in producing THCV here. If that's the case, would that be something Cronos would find economically interesting, considering the availability of THCV — THC today in markets around the world?
Mike Gorenstein
executiveThat's a really good question. I think when we examined this during prioritization, one thing we deliberately did was put the rare cannabinoids first, simply because there's already plenty of THC and CBD. The value for us in using Canada to develop borderless products and launch them lies in making sure the actual product is tested in the market, so that when other markets open, we're ready. So setting aside what I'd call the financial viability, just from the standpoint of the logistics — getting Cronos Fermentation set up and ready to run production for various products — it makes sense for us to put rare cannabinoids first. Once that's finished and operating, however, we still plan to include THC and CBD among the rare cannabinoids that have been in our deal from the beginning. Do we have another question on the line?
Operator
operatorAndrew Carter from Stifel is joining us on the call.
W. Andrew Carter
analystTo start, I’d like to ask about how Spinach flower has been performing in Canada. You mentioned the bags, but from what we see in the headset data, your 28-gram bag is up 202% sequentially, while your 8 and 7 ounce sizes fell 35%. So my first question is whether your pricing is right on the 8 ounce, and whether the 28-gram bag is taking volume from it. I’m also frankly surprised by the emphasis on the 28-gram bag. Can that be profitable incrementally, given that many other LPs have taken this approach and seen diminishing returns? That’s my first question.
Mike Gorenstein
executiveOkay, so overall in flower, I think we've continued to grow faster than the market on a year-over-year basis — we were up 36% while the market was flat. And what we're really seeing, I think, is a significant move away from smaller pack sizes toward 28-gram. Now, a lot of those 28-gram bags you've come across have naturally been heavily value-oriented, but we have seen that demand still exists for Spinach and for the tier we play in at 28 grams. So we're doing that while holding onto our brand and price positioning. But there certainly is some cannibalization. And I think we faced the decision that if that's where consumers are going, we want to be in a position to give our consumers what they're after.
W. Andrew Carter
analystAnd could a 28-gram bag be a profitable route for growth?
Mike Gorenstein
executiveYeah, I'd agree, particularly when you consider how costs get absorbed on the packaging side, and with our realignment shifting things to GrowCo, we end up with a stronger cost structure for flower as a whole.
W. Andrew Carter
analystMy second question concerns the change in emphasis within the U.S., the greater sort of adult emphasis, which is going to be fairly — I mean, not that beauty wasn't performing well, but that will be a fairly narrow sort of market focus. I suppose, can that segment by itself, with only the market opportunities at hand, be a profitable one? Or is there some annual sort of loss or burn you're prepared to sustain in that segment just to sort of keep it alive and hold a toehold for any potential favorable regulatory developments down the road?
Mike Gorenstein
executiveAbsolutely. We do think this can be a profitable segment, which is why you’re seeing the emphasis. We’re focused on what actually reaches the bottom line. As you’re suggesting, when you compare revenue with profit, not every dollar of revenue carries the same value. Our margin profile is considerably stronger in DTC than in wholesale Beauty. I’d add that when we discuss adult-use product formats, CBD is one cannabinoid that belongs in that conversation, but other cannabinoids remain as well. You’re seeing us work on various rare cannabinoids. For us, what matters is the product format that can ultimately match consumer demand across our full suite of cannabinoids. So I’d describe this quarter as involving some contraction and becoming somewhat more flexible and agile, which positions us to grow over the longer term and aligns better with where our focus lies.
Operator
operatorAndrew Bond from Jefferies has our next question.
Andrew Bond
analystAndrew here, speaking on behalf of Owen Bennett. My first question concerns the international side. I appreciate the detail you provided regarding Israel and some of the regulatory challenges and price competition you're encountering there. However, looking beyond Israel, we're also aware that you hold a position in Germany, a market that has seen some encouraging developments in recent weeks. So my first question — perhaps this is for you, Mike — could you remind us how you're positioned in the German market? And is there any update on your strategic outlook for that market? That would be great.
Mike Gorenstein
executiveAbsolutely. So in Germany, we have a distribution partnership with Pohl-Boskamp, and it's mostly flower sales. There's a great deal of activity in Germany at the moment. And I think there's a lot of discussion. In our view, it can be a very strong market. It's definitely a market we're focused on. I'm not sure that's the next 6 to 12 months. When we believe there's movement, we'll be ready. But it looks like it's probably a little over a year away. Our best estimate right now is 2024. And I think certain things need to be worked out when it comes to dynamics. But our view is that ultimately, in any market, particularly in an adult-use market, having the best branded product portfolio is what will lead to success. And we feel that continuing to preserve our balance sheet flexibility lets us move in and secure the right infrastructure to support our getting our products out into the market. And so in parallel, continuing to develop SOURZ and FEELZ, our vape line and pre-rolls, is what will lead to us winning in Germany.
Andrew Bond
analystAnd as a quick follow-up, a housekeeping item about gross margins, perhaps for you, Bob. Could you characterize or help quantify how margins were affected by under absorption of fixed cost resulting from production that ceased at Peace Naturals? I just want to get a sense of what underlying gross margins might be, given some of the favorable items you mentioned — positive mix and reduction in purchasing costs?
Robert Madore
executiveYes. You just need to remove the depreciation adjustment that came from our activities, along with the realignment and the move out of Stayner. When you look at gross margin without that depreciation change, the margin rates for Q1 and Q2 are fairly similar when all is said and done. The difference is probably 3 percentage points. Part of that really relates in Q2 to the U.S. segment and to the inventory reserves and other items we took as part of the realignment repositioning, but it's fairly — it's a very comparable margin rate for Q1 versus Q2, and a significant improvement versus prior year. So hopefully that answers your question, if you take out the noise around depreciation or absorption, the under-absorption of fixed costs.
Operator
operatorVivien Azer from Cowen has our next question.
Vivien Azer
analystI'd like to ask a follow-up on a few of the U.S. points, Mike, if I may, regarding moving Lord Jones into adult-use form factors. How do you plan to protect brand equity and, in the end, build it up further, given that this was a business so centered on topicals? And specifically, what do you mean by adult-use form factors?
Mike Gorenstein
executiveOf course. I believe you recall the Lord Jones brand from its call it THC era, but for me, Lord Jones has always really been a gumdrop brand first. That was the initial hero SKU, and I think that's what it grew famous for. What I want to ensure is that we become well known again among cannabis consumers. And I think it's quite hard to sort of begin pursuing beauty and cannabis simultaneously. So making sure we're on the form factor that, even if it isn't Delta-9 THC today, right, can pivot later on. So we just launched CBN in Canada. So certainly, you can see we're moving to other form factor -- or sorry, other cannabinoids within the same form factors. And I think cannabis consumers do seek out other cannabinoids that aren't solely THC.
Vivien Azer
analystTurning to Israel, it's encouraging that you highlighted a sequential gain in patient adds. Still, how would you characterize where that market sits regarding penetration rates across the total population?
Mike Gorenstein
executiveAbsolutely. I'd say we're still at a very, very early stage. Some physicians who had been prescribing historically ran into problems, and we haven't been able to prescribe through them over the last few months. Our understanding is that there's a fair amount of pent-up demand. And we believe that today's patient count could — depending on how the regulatory environment develops — quite easily double or triple if we had something that opened things up a bit more smoothly. So I don't think we're anywhere near close to penetrating that population. I think you have the highest consumption in Israel, or really in any country worldwide. So 116,000 patients is really only scratching the surface.
Vivien Azer
analystYes, got it. But when you consider that chance to double or triple, how would you go about benchmarking it? Would it resemble Florida, or would it resemble Oklahoma? Is that even a fitting comparison?
Mike Gorenstein
executiveAbsolutely. Florida, I'd call it a market unlike any other, which makes comparisons there fairly tough. One factor that becomes really challenging when you consider Israel is simply that the illicit market differs enormously from what you see across North America. As a result, it's somewhat more captive. Turning to Oklahoma, there are plenty of intriguing dynamics surrounding that state too. My view is that it resembles Colorado as it approaches maturity, yet I also believe it will prove to be a rather lucrative medical market, and finding a comp will likely be difficult. Considering the size of the population, considering consumption and overall attitudes toward cannabis, my sense is that over the long term it looks a bit like Colorado.
Operator
operatorShaan Mir from Canaccord Genuity has our next question.
Shaan Mir
analystStarting with the Ginkgo Bioworks relationship — I just want to understand the export potential tied to the cultured cannabinoid products that come out of it. Any anecdotes you could share about what hurdles would have to be cleared in order to export those products? And how might that differ from the process used today for exporting THC-based products?
Mike Gorenstein
executiveYes. It really varies by country. Many nations have programs that are similar to Canada's. And when the language is the same as Canada's, there won't be any problems. Some markets — and I think a lot of the newer ones you're seeing are still flower markets, or mainly flower-only markets. So until that opens up, it's really more of an opportunity for exporting flower. Every market is quite different, but the expectation is that as markets mature, you'll see us able to supply a data set so it gets treated the same as other cannabinoids. So for me, the biggest issue is getting different types of extracts and derivative products to open up.
Shaan Mir
analystTurning to another topic, I'd like to dig a bit deeper into how large your partnership with Geocann actually is and how the rollout of the — I'm not sure I'm saying this correctly — that delivery technology is going. Do you intend to use that technology across your whole product platform, THC items included? Or is it limited to products made with CBD? Basically, would you move your existing lineup of edibles and other derivatives over to that technology? And if that's the plan, could you address what considerations or investments Cronos would need to make for it? And are there any advantages to doing so?
Mike Gorenstein
executiveOkay. At present, the sole offering we have disclosed that incorporates this technology is the gel capsules sold in the U.S. That said, let me note that whenever we consider our product lineup and what consumers are looking for, there has always been a kind of matrix. On one side, we discuss product format — the various categories of edibles such as the gummy platform, vapes, and pre-rolls — and on the other side, we discuss effects, and typically you'll hear us describe that in terms of the specific cannabinoid formulas we offer. So is it THCV, is it CBC, is it THC. Yet part of the effects, beyond those cannabinoids, is timing as well. So which type of multiplication are you using for onset and offset. So this is something that has been taken into account, and we've conducted consumer research. It's something we believe there is substantial demand for among consumers, and it's something we believe can be extremely, extremely beneficial for the portfolio. But I wouldn't view it as a cutover there. To illustrate with edibles, plenty of people have grown used to waiting for the onset when it comes to edibles.
Mike Gorenstein
executiveThey find a ritual in it, a sense of comfort, and that appeals to them. Some other folks would rather it moved more quickly. So honestly it comes down to the product in question, the way we'd formulate it, and the approach we'd take. Still, I'd anticipate considerably more innovation coming from us, and a great deal of effort has already gone into what we do with onset and offset.
Operator
operatorWe appreciate everyone joining this call today. That brought us to the final question. With that, we're wrapping up the program. You're free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.